Cover Image
市場調查報告書

Allergan, Inc. - 產品平台評估

Allergan, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224564
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
Allergan, Inc. - 產品平台評估 Allergan, Inc. - Product Pipeline Review - 2015
出版日期: 2015年03月26日 內容資訊: 英文 83 Pages
簡介

Allergan, Inc. 是開發並商品化新型治療藥、一般成藥、生技藥品、醫療設備,及其他針對特殊市場產品的全球性醫療相關企業。

本報告提供Allergan, Inc. 的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Allergan, Inc.的基本資料

Allergan, Inc.概要

  • 主要資訊
  • 企業資料

Allergan, Inc.:R&D概要

  • 主要的治療範圍

Allergan, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Allergan, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Allergan, Inc.:藥物簡介

  • dexamethasone acetate
  • dihydroergotamine mesylate
  • Aczone X
  • AGN-229666
  • bimatoprost
  • cyclosporine
  • desmopressin acetate
  • onabotulinumtoxinA
  • oxymetazoline hydrochloride
  • (bimatoprost + brimonidine tartrate)
  • AGN-150998
  • beclomethasone dipropionate
  • bimatoprost SR
  • brimonidine tartrate implant
  • senrebotase
  • AGN-223575
  • AGN-151200
  • Drug to Activate GABA Receptor for Epilepsy
  • Drug to Inhibit Tyrosine Kinase for AMD
  • Small Molecule For Glaucoma
  • Small Molecule to Agonize D2/D3 Receptors for Parkinsons Disease
  • Neurotoxin Program

Allergan, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Allergan, Inc.:最近的開發平台趨勢

Allergan, Inc.:暫停中的計劃

Allergan, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • budesonide
    • dexamethasone acetate
    • EHT/AGN-0001
    • IRX-4310
    • memantine hydrochloride
    • onabotulinumtoxinA

Allergan, Inc.:企業發表

Allergan, Inc.:總公司和子公司的所地

Allergan, Inc.:主要製造設備

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06889CDB

Summary

Global Markets Direct's, 'Allergan, Inc. - Product Pipeline Review - 2015', provides an overview of the Allergan, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Allergan, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Allergan, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Allergan, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Allergan, Inc.'s pipeline products

Reasons to buy

  • Evaluate Allergan, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Allergan, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Allergan, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Allergan, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Allergan, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Allergan, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Allergan, Inc. Snapshot
    • Allergan, Inc. Overview
    • Key Information
    • Key Facts
  • Allergan, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Allergan, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Allergan, Inc. - Pipeline Products Glance
    • Allergan, Inc. - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Allergan, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Allergan, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Discovery Products/Combination Treatment Modalities
    • Allergan, Inc. - Drug Profiles
    • dihydroergotamine mesylate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Aczone X
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AGN-229666
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bimatoprost
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bimatoprost SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • desmopressin acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • onabotulinumtoxin A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oxymetazoline hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (bimatoprost + brimonidine tartrate)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • abicipar pegol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AGN-195263
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • beclomethasone dipropionate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brimonidine tartrate implant
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lidocaine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • senrebotase
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AGN-223575
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AGN-151200
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Agonize D2/D3 Receptors for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Agonize GABA Receptor for Epilepsy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit Tyrosine Kinase for AMD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Glaucoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Neurotoxin Program
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Allergan, Inc. - Pipeline Analysis
    • Allergan, Inc. - Pipeline Products by Target
    • Allergan, Inc. - Pipeline Products by Route of Administration
    • Allergan, Inc. - Pipeline Products by Molecule Type
    • Allergan, Inc. - Pipeline Products by Mechanism of Action
  • Allergan, Inc. - Recent Pipeline Updates
  • Allergan, Inc. - Dormant Projects
  • Allergan, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • budesonide
      • dexamethasone
      • memantine hydrochloride
      • onabotulinumtoxin A
  • Allergan, Inc. - Company Statement
  • Allergan, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Allergan, Inc. - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Allergan, Inc., Key Information
  • Allergan, Inc., Key Facts
  • Allergan, Inc. - Pipeline by Indication, 2015
  • Allergan, Inc. - Pipeline by Stage of Development, 2015
  • Allergan, Inc. - Monotherapy Products in Pipeline, 2015
  • Allergan, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Allergan, Inc. - Partnered Products in Pipeline, 2015
  • Allergan, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Allergan, Inc. - Out-Licensed Products in Pipeline, 2015
  • Allergan, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Allergan, Inc. - Filing rejected/Withdrawn, 2015
  • Allergan, Inc. - Phase III, 2015
  • Allergan, Inc. - Phase II, 2015
  • Allergan, Inc. - Phase I, 2015
  • Allergan, Inc. - Preclinical, 2015
  • Allergan, Inc. - Discovery, 2015
  • Allergan, Inc. - Pipeline by Target, 2015
  • Allergan, Inc. - Pipeline by Route of Administration, 2015
  • Allergan, Inc. - Pipeline by Molecule Type, 2015
  • Allergan, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Allergan, Inc. - Recent Pipeline Updates, 2015
  • Allergan, Inc. - Dormant Developmental Projects,2015
  • Allergan, Inc. - Discontinued Pipeline Products, 2015
  • Allergan, Inc., Subsidiaries
  • Allergan, Inc., Key Manufacturing Facilities

List of Figures

  • Allergan, Inc. - Pipeline by Top 10 Indication, 2015
  • Allergan, Inc. - Pipeline by Stage of Development, 2015
  • Allergan, Inc. - Monotherapy Products in Pipeline, 2015
  • Allergan, Inc. - Partnered Products in Pipeline, 2015
  • Allergan, Inc. - Pipeline by Top 10 Target, 2015
  • Allergan, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Allergan, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Allergan, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top